Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.92 - $84.91
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.05M
Market Cap
$12.91B
Enterprise Value$12.24B
Total Cash (Recent Filing)$19.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 01, 2025EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.59
Shares Outstanding181,820,000
10 Day Avg. Volume2,996,943
30 Day Avg. Volume2,051,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)39.77
Price to Cash Flow (P/CF)-18.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit44.03
Enterprise Value/Ebitda-14.42
Forecast
1Y Price Target
$98.00Price Target Upside37.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceStrong 4Q24 ex-US sales lead to a higher revenue estimate for Arikayce in 2025, reflecting improved company performance.
Market PotentialTPIP, a prodrug of treprostinil, offers compelling advantages over its parent molecule, a mainstay for pulmonary hypertension, with potential to capture over 60% of the market.
Product DifferentiationSignals and initial data support the potential for once daily dosing of TPIP, a critical differentiator and key to its commercial opportunity.
Regulatory ConfidenceThere is a 90% confidence in FDA approval for brensocatib, which could lead to a new trajectory for INSM.
Bears Say
Competitive ConcernsConcerns exist over the continued use of treprostinil in PAH given the launch of Merck’s sotatercept.
Market PerceptionTPIP could well capture over 60% of the market, yet investors are pricing in a likelihood of success of only 20-40%.
---
Ownership Overview
1.28% Insiders
35.37% Mutual Funds
0.40% Other Institutional Investors
46.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $21.92 and its highest was $84.91 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $12.91B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is May 01, 2025 which is in 15 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Feb 20, 2025. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.171 by -$0.149.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -1.34.
How many shares outstanding does Insmed have?
Insmed has 181,820,000 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.171. Following the earnings report the stock price went down -0.262%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
---
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.00 (37.97% Upside)
$98.00 (37.97% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 813.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
160.66%
12-Months-Change
Fundamentals
Return on Equity
-320.20%
Trailing 12-Months
Asset Growth
52.29%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
---
INSM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Insmed, highlighting record revenue growth for ARIKAYCE, successful clinical trials, and a strong cash position, despite acknowledging some challenges related to cash burn and market access strategies.Read More>---
INSM Stock 12 Month Forecast
Average Price Target
$98.00
▲(37.97% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Corcept Therapeutics
―
Incyte
―
United Therapeutics
―
Intra-Cellular Therapies
―
Best Analysts Covering INSM
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+84.00%
reiterated a buy rating 29 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +84.00% per trade.
---